Drug
Aav5 Hrkp Rpgr
Aav5 Hrkp Rpgr: highest development phase Phase 3, developed by MeiraGTx. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAV5-hRKp.RPGR NCT05926583 | Phase 3 | Retinitis Pigmentosa |
| AAV5-hRKp.RPGR NCT06646289 | Phase 2 | X-Linked Retinitis Pigmentosa |
Latest
No recent events.
Follow Aav5 Hrkp Rpgr on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.